The international market demand for API is low
Source:
|
Author:pmo626b20
|
Published time: 2017-06-02
|
2564 Views
|
Share:
Reporters recently learned that, as a major exporter of raw materials, China's raw materials into the European and American markets encountered no small problems. In the first half of this year, the import and export volume of China's pharmaceutical trade reached US $43 billion 237 million, an increase of 10.28% compared with the previous year.
Reporters recently learned that, as a major exporter of raw materials, China's raw materials into the European and American markets encountered no small problems. In the first half of this year, the import and export volume of China's pharmaceutical trade reached US $43 billion 237 million, an increase of 10.28% compared with the previous year. Since the third quarter, however, China's raw material exports have entered the most difficult period in Europe and the United states.
Low export growth
APIs have been regarded as low value-added products, but they have played an important role in the development of Chinese medicine and foreign trade. At present, China has become the world's largest producer and exporter of raw materials, and China is the world's leading source of bulk drug supply. However, this year, the overall demand for raw materials international market downturn.
Due to the shortage of capital, foreign customers to reduce inventory and purchase quantity, pay more attention to the price inquiry more, a single, long single into a small, leading to domestic enterprises competition, competition for customers, so that Analginum, aspirin and other antipyretic analgesics bulk raw material export decline.
According to customs statistics China China collected by the chamber of Commerce, the first half of 2013, China raw material exports amounted to $12 billion 112 million, an increase of 3.08%; export volume of 3 million 339 thousand and 300 tons, an increase of 7.46%; the average export price fell by 4.07%. Export growth is still low.
Pharmaceutical overcapacity
The rigid demand in the pharmaceutical market determines the demand for api. China's huge production capacity needs to be digested through the international market, so that China's export of API will maintain steady growth in quantity. At present, the bulk raw material overcapacity, fierce competition, coupled with the slow economic recovery in the developed countries, devaluation of emerging market countries, leading to raw materials export price is rising, but increase the cost also makes the export price not much decline in space.
Anhui, a medium-sized pharmaceutical company general manager Li Jian told reporters that the technical threshold is low, capacity replication easily, product differentiation is part of the main cause of excessive production of bulk drug products one of the reasons. Especially in the new version of GMP (GMP) in the process of rapid improvement, investment in fixed assets is extremely easy to make technical content is not high relative to the raw materials manufacturing overcapacity problem, and bring down the profits of the whole industry, resulting in a vicious competition.
Li Jian also said that another major reason for the decline in export profits is the ability to digest environmental costs is not strong, environmental standards accelerated too fast. On the one hand, all costs are rising, on the other hand is the terminal of drug price continues to decline, it is very difficult for raw materials enterprises, unless the enterprise has a strong bargaining power, but the raw materials of this product is not a lot. In addition, the appreciation of the RMB has also increased the export pressure of bulk raw materials and intermediate products with lower added value. Li Jian said that the continued appreciation of the RMB has seriously affected the export of enterprises, China's export of raw material drugs in the price competition advantage is gradually lost, and the operation of export enterprises have also formed a certain pressure.
Vigorously develop emerging markets
Li Jian also said that the raw material enterprises only through technological innovation, so that their production techniques continue to upgrade, in order to allow enterprises to improve export profits. This virtually enhances the confidence of enterprises to continue to innovate and forms a sound development pattern. At the same time, the pharmaceutical industry should also introduce more stringent regulatory measures to combat environmental protection, quality standards of non-compliance of enterprises, to avoid disorderly and vicious competition, to protect the healthy and sustainable development of the API industry.
In the face of this round of raw materials export market downturn, medical professionals have said should respond positively, continue to vigorously explore the international market, to expand the international market share, and actively participate in regional economic cooperation, and effectively solve various problems; seize the new round of the global pharmaceutical industry in Asia to transfer opportunities, improve the ability to undertake international pharmaceutical industry transfer and absorbing the. Reporters found in the survey, in the global economic downturn, and sluggish demand for medicine in the background, emerging markets almost become China's major export of pharmaceutical raw materials the only way out. Data show that in the first half, China's bulk drug exports to emerging markets increased by 10.03%. Among them, large and medium-sized pharmaceutical enterprises have stepped up efforts to develop emerging markets and African markets, and the number of manufacturers of 100 pharmaceutical enterprises in emerging markets has increased by 12.2%.
Insiders said that the two most worthy of mention in emerging markets are Russia and Nigeria in africa. In recent years, Russia and China trade more and more, the drug trade, two countries currently in the medical security system level, application level are relatively similar, the drug market entry threshold is lower than America, EU exports to Chinese, these drugs are extremely beneficial. In addition, Nigeria is also a potential export market, which is located in the pharmaceutical industry base is very weak in Africa, is the drug trade concentration in Africa, and Chinese has always attached great importance to trade with Africa, and the establishment of the Sino African trade fund, specialized services in small enterprises of non trade.
